![]() The primary outcome (change in HbA1c level at month 6) will be measured by a laboratory that isīy staff / FebruGet help monitoring glucose levels and more with this plain but functional diabetes-management program. Masking the arm allocation will be precluded by the behavioural nature of the intervention but blocking size will not be disclosed to protect concealment. new glucometer users) into three arms, namely (1) usual care (UC) only, (2) UC with process incentive and (3) UC with outcome incentive, in a 2:3:3 ratio. ![]() A total of 240 patients with suboptimally controlled diabetes (HbA1c 8%) from a polyclinic in Singapore are block-randomised (blocking factor: current vs. TRIAD is a randomised, controlled, open-label, single-centre superiority trial with three parallel arms. In the Trial to Incentivise Adherence for Diabetes (TRIAD) we test whether adding financial incentives to usual care can improve HbA1c levels among people with diabetes and whether the financial incentives work better when targeting processes (adherence to blood glucose testing, medication, and daily physical activity) or the primary intermediary health outcome of self-monitored blood glucose within an acceptable range. Whereas there is evidence that rewards can improve treatment adherence and sometimes health outcomes, further research is needed to determine whether rewards are more effective when targeting processes or intermediary health outcomes. One strategy to address this discontinuity is to offer patients a near-term benefit, such as a financial reward. Behavioural economic theory suggests that the lack of adherence results from the disconnect between the timing of when costs and benefits accrue. Trial to Incentivise Adherence for Diabetes (TRIAD): study protocol for a randomised controlled trial Many people with diabetes have suboptimal glycaemic control due to not being adherent to their treatment regimen. For more information, visit and SOURCE Lifescan, Inc.Trial To Incentivise Adherence For Diabetes (triad): Study Protocol For A Randomised Controlled Trial For over 35 years, LifeScan has had an unwavering commitment to improving the quality of life for people with diabetes by developing products defined by simplicity, accuracy, and trust. With a vision to create a world without limits for people with diabetes, LifeScan is a world leader in blood glucose monitoring – globally more than 20 million people depend on OneTouch brand products to help them manage their diabetes. Through our partnership with LifeScan and their cutting-edge technology, we believe we can help even more people who are living with Diabetes to more easily adopt long-term lifestyle habits that help them live healthy lives." "At Noom, we help people leverage the latest science and technology to create healthy habits that stick. And yet it can be a real struggle to make the healthy choice day after day, meal after meal," said Saeju Jeong, CEO of Noom. ![]() "Most people living with type 2 diabetes know how important it is to control their blood sugar and weight. Millions of people have benefited from Noom's behavior change courses, including its virtual diabetes prevention program, which was the first of its kind to be recognized by the CDC. ![]() The OneTouch Reveal app is one of the most downloaded diabetes apps in the world and OneTouch has been named the #1 Pharmacist Recommended Brand by Pharmacy Times/U.S. "Our intention is to create a powerful, supportive digital solution for people with diabetes that helps them meet their diabetes management and weight loss goals and generates better outcomes for all involved in the healthcare system." "With this pilot program, we are combining OneTouch's unmatched expertise in diabetes, blood glucose management and digital health with Noom's disruptive technology that combines the power of artificial intelligence, mobile tech, and psychology to help people manage their diabetes, lose weight and live a healthier life," says Val Asbury, LifeScan CEO & President. The pilot program will include select OneTouch patients and track clinical outcomes as well as patients' experience and satisfaction with the program. Through this pilot, people with type 2 diabetes using the OneTouch Reveal app, a mobile diabetes management tool that can help people with diabetes remotely track their blood sugar from their wireless device and easily share results with their healthcare team and loved ones, will get free access to OneTouch Reveal and Noom's Diabetes Management Program, integrated through Apple Health Kit. LifeScan announces collaboration with Noom® to launch pilot program integrating OneTouch Reveal® app with Noom’s digital diabetes and weight loss management program.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |